Skip to main content
European Commission logo print header

Innovation in Tuberculosis

Descripción del proyecto

Desarrollo innovador para permitir el tratamiento individualizado de la tuberculosis

La tuberculosis (TB) está causada por las bacterias «Mycobacterium tuberculosis» y es una de las principales enfermedades infecciosas en todo el mundo. Los métodos convencionales de diagnóstico y de prueba de susceptibilidad a fármacos no son lo suficientemente eficaces para controlar la enfermedad, y todos los pacientes con TB siguen la misma duración del tratamiento, lo que a veces da lugar a incidentes adversos, poca adherencia a las directrices del tratamiento y malos resultados. El equipo del proyecto INNOVA4TB, financiado por las Acciones Marie Skłodowska-Curie, aspira a introducir tecnologías y métodos innovadores para evaluar el riesgo de progresión de la TB, el diagnóstico rápido y la prueba de susceptibilidad a fármacos de la cepa en cada persona. Esto dará lugar a tratamientos a medida con una duración individualizada del tratamiento antimicrobiano.


The objective of INNOVA4TB is to enhance and strengthen the collaborative research among sectors and to form a network aimed to perform high-quality and translational research in the field of diagnosis and management of tuberculosis (TB). The consortium is constituted by 12 institutions from 8 countries that combine complementary and synergic expertise: clinical management (hospitals), basic science and new technologies (academic institutions), and industrial development and entrepreneurship culture (SMEs). The exchanges between the institutions allow the participants to progress in their career perspectives.
TB is one of the major infectious diseases worldwide, and the emergence and spread of drug resistant cases is a public health threat. However, the conventional methods used for diagnosis and drug-susceptibility testing are not enough for controlling the disease. In addition, all TB patients, independently of their age, gender, severity of the disease and type of responsible strain, follow the same treatment duration (up to 20 months in drug resistant cases), which often leads to high frequency of adverse events, suboptimal adherence to treatment, and poor outcome. A transition from programmatic to personalized management of TB is needed. Our proposal will develop innovative technologies and approaches in order to improve the individual risk assessment for TB development, to rapidly diagnose active TB, to detect the drug susceptibility of the strain, to design tailor-made therapies, and to use biomarkers to guide and individualize the duration of antimicrobial therapy. This is of great importance for improving the quality of life of patients and ensuring treatment success, as well as for economic reasons for the healthcare system.


Aportación neta de la UEn
€ 327 106,00
08916 Badalona Barcelona

Ver en el mapa

Este Cataluña Barcelona
Tipo de actividad
Research Organisations
Coste total
€ 327 106,00

Participantes (14)

Socios (1)